Intervention effect and dose-dependent response of Tanreqing injection on airway inflammation in lipopolysaccharide-induced rats  by Dong, Shoujin et al.
TOPIC
JTCM |www. journaltcm. com August 15, 2013 |Volume 33 | Issue 4 |
Online Submissions: http://www.journaltcm.com J Tradit Chin Med 2013 August 15; 33(4): 505-512
info@journaltcm.com ISSN 0255-2922
© 2013 JTCM. All rights reserved.
EXPERIMENTAL STUDY
Intervention effect and dose-dependent response of Tanreqing in-
jection on airway inflammation in lipopolysaccharide-induced rats
Shoujin Dong, Yunqing Zhong, Kun Yang, Xiaoling Xiong, Bing Mao
aa
Shoujin Dong, Bing Mao, Pneumology Group, Department
of Integrated Traditional Chinese and Western Medicine,
West China Hospital, West China School of Medicine, Sich-
uan University, Chengdu 610041, China
Yunqing Zhong, Department of Respiratory Medicine, The
First Affiliated Hospital of Guangxi Traditional Chinese Medi-
cal University, Nanning 530023, China
Kun Yang, Department of Geratology, Chengdu University
of Traditional Chinese Medicine, Chengdu 610041, China
Xiaoling Xiong, Department of Geratology, Sichuan Hospi-
tal of Integrated Traditional Chinese and Western Medicine,
Chengdu 610041, China
Supported by the Program for Innovative Research at the
West China School of Medicine, Sichuan University, and Sich-
uan Technology Department (No. 2012SZ0288)
Correspondence to: Prof. Bing Mao, Pneumology Group,
Department of Integrated Traditional Chinese and Western
Medicine, West China Hospital, West China School of Medi-
cine, Sichuan University, Chengdu 610041, China. wuming-
shoujin@sina.com
Telephone: +86-13438836526
Accepted: December 20, 2012
Abstract
OBJECTIVE: To assess the effect of Tanreqing injec-
tion on airway inflammation in rats.
METHODS: A rat model of airway inflammation
was generated with lipopolysaccharide (LPS). Tan-
reqing injection was given by intratracheal instilla-
tion, and bronchoalveolar lavage fluid (BALF) from
the right lung was collected. BALF total cell and
neutrophil counts were then determined. In addi-
tion, BALF levels of inflammatory cytokines inter-
leukin-1β, cytokine-induced neutrophil chemoat-
tractant-1, and tumor necrosis factor-α were mea-
sured using enzyme linked immunosorbent assay.
The middle lobe of the right lung was stained with
hematoxylin-eosin and histological changes exam-
ined.
RESULTS: LPS increased airway inflammation, de-
creased BALF inflammatory cell count, inflammato-
ry cytokine levels, and suppressed leukocyte influx
of the lung. The LPS-induced airway inflammation
peaked at 24 h, decreased beginning at 48 h, and
had decreased markedly by 96 h.
CONCLUSION: Tanreqing injection contains anti-in-
flammatory properties, and inhibits airway inflam-
mation in a dose-dependent manner.
© 2013 JTCM. All rights reserved.
Key words: Pulmonary disease, chronic obstruc-
tive; Lipopolysaccharides; Dose-response relation-
ship, drug; Airway inflammation; Tanreqing injec-
tion
INTRODUCTION
In recent years, the pathogenesis, diagnosis and treat-
ment of chronic obstructive pulmonary disease
(COPD) has been the subject of a number of studies
examining the role of inflammatory cells and secretory
factors. Persistent airway inflammation is an important
feature of COPD when exacerbated beyond the station-
ary phase. Neutrophils, CD68 + monocytes/macro-
phages and CD8+ T lymphocytes are key inflammato-
ry effector cells. Neutrophils and macrophages infil-
trate the lumen, and lymphocytes infiltrate the tracheal
wall.1 Alveolar macrophages, epithelial cells, and neu-
trophils produce various cytokines, including interleu-
kin-1β (IL-1β), tumor necrosis factor-α (TNF-α), leu-
kotriene B4 (LTB4), and interleukin-8 (IL-8).2 In
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COPD patient sputum and bronchoalveolar lavage flu-
id (BALF), the number of activated neutrophils increas-
es, whereas there are fewer neutrophils in the airway
and lung parenchyma than in the lumen. Neutrophils
secrete neutrophil elastase (NE), cathepsin G, protease
3, MMP-8, MMP-9, and other serine proteases and ox-
idizing agents, all of which damage alveolar tissue.3
Studies show that patient lung airflow is obstructed,
with an increase in neutrophil count. The neutrophil
count in the bronchial mucosa and induced sputum
correlates with the seriousness of the illness.4 In the
acute exacerbation period of COPD, a large number of
inflammatory cells are activated, with aggregation and
infiltration, and they release a variety of cell factors
that aggravate airway inflammation. Alveolar macro-
phages secrete MMP-2, MMP-9, MMP-12, cathepsin
K, and fiber dissolving enzymes that destroy alveolar
structures. As might be expected, the macrophage cell
count correlates with COPD severity.3,5
In COPD patients, T lymphocyte counts in lung pa-
renchyma, and central and peripheral airway increase,
with CD8 + T lymphocyte numbers increasing more
than CD4+ T lymphocytes.6
For the COPD patients in the stationary phase, regular
inhalation of glucocorticoids and anti-inflammatory
drugs can improve symptoms and quality of life by re-
ducing the frequency of acute exacerbations.7 However,
it is still controversial whether such treatment inhibits
airway inflammation. Gan et al 8 describe evidence-based
medicine used to systematically evaluate the effect of
inhaled corticosteroids on sputum cell counts in sta-
tionary phase COPD patients. The results indicate that
long-term corticosteroid inhalation reduces airway in-
flammation in stationary phase COPD patients. How-
ever, efficacy and safety remain to be further examined.
Several preliminarily animal reports examined curative
effects and drug mechanisms for stimulating blood cir-
culation (Danshen injection), dispersing lung Qi and
expelling pathogenic heat (modified Yuepibanxia decoc-
tion), clearing heat and removing toxic substances
(Flos Lonicerae), or invigoration (compound Runfei
oral liquid), and found that some Chinese drugs have
certain therapeutic effects on COPD airway inflamma-
tion. Yue et al 9 adopted LPS injection in the airway us-
ing fumigation and smoking to establish a COPD rat
model. Intraperitoneal Danshen injection was used to
intervene and determine white blood cell counts, neu-
trophil counts, and BALF IL-8 levels. Rats receiving
Danshen injections exhibited lower cell counts and Il-8
levels than controls, indicating that Danshen injection
has a certain inhibitory action on airway inflammation
in the COPD model examined. Li et al 10 used LPS in-
stillation into the airway and cigarette smoking to es-
tablish COPD airway inflammation in the rat model
and to study the effects of a Modified Yuebi Jiabanxia
decoction on lung morphology. Serum IL-8 and
TNF-α levels indicated that lung tissue morphology,
and IL-8 and TNF-α levels after intervention were de-
creased compared with controls, suggesting that it may
be effective at alleviating airway inflammation. Lee et
al 11 found that honeysuckle extract reduces the total
cell count, neutrophil count, and IL-6 and TNF-α lev-
els in mouse BALF and airway inflammation induced
by LPS, relieving pulmonary inflammatory cell infiltra-
tion. This indicates that honeysuckle extract has a cer-
tain preventive and therapeutic effects on LPS-induced
airway inflammation. Liu et al 12 reported that Runfei
oral liquid down-regulates IL-6 and TNF-α expression
and reduced airway inflammation.
In the present study, a LPS-induced airway inflamma-
tion rat model was established by injection of LPS into
the airway. Airway inflammation was evaluated by to-
tal cell count, neutrophil count, and IL-β1, cyto-
kine-induced chemoattractant-1 (CINC-1), and TNF-α levels in BALF, and pathological changes to bronchi-
al lung. The intervening effects of Tanreqing injection
on LPS-induced airway inflammation and the dose-re-
sponse relationship was subsequently investigated.
MATERIALS ANDMETHODS
Experimental animals
Specific pathogen-free adult male Sprague-Dawley rats,
weighting 200-250 g, were purchased from the Bill An-
imal Farm of Jianyang (Jianyang, China). All rats were
adaptively fed for 5 days.
Drugs and reagents
Escherichia coli 055 and paraformaldehyde were pur-
chased from Sigma (St. Louis, MO, USA). Tanreqing
was purchased from Kai Bao Pharmaceutical Company
(Shanghai, China). Erythrocyte lysis buffer was pur-
chased from Beyotime Institute of Biotechnology
(Shanghai, China). Wright stain was purchased from
Begen Company (Fujian, China). Rat IL-1β ELISA kit
was purchased from Shanghai ExCell Biology Compa-
ny (Shanghai, China). Rat CXCL-1/CINC-1 and Rat
TNF-α ELISA kits were purchased from USA R&D
Systems (Minneapolis, MN, USA). Pentobarbital sodi-
um P8410-5 was purchased from Sanofi Ceva (Han-
nover, Germany).
Model generation
The airway inflammation model was prepared accord-
ing the modeling method of Ou et al 13 with modifica-
tions. Rats were anesthetized by intraperitoneal injec-
tion of 4% pentobarbital sodium (40 mg/kg) and fixed
on a rat board. After local disinfection, a neck midline in-
cision of 1.5 cm was made by blunt separation to expose
the trachea. The trachea was punctured with a 1 mL sy-
ringe, and 120 μL (2 g/L) LPS was slowly injected into
the airway, once per rat. Rats were gently shaken up-
right for about 2 min to uniformly distribute LPS in
the lungs. The neck skin was then sutured and disin-
fected.
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Experimental animal groups
The rats were randomly divided into a blank control,
model, low dose Tanreqing intervention, and high dose
Tanreqing intervention groups, with 12 rats in each
group. The low and high dose Tanreqing groups were
defined with respect to the published animal weight
and dose conversion factors.14,15 Animals were sacrificed
(4/group/batch) at 24, 48, and 96 h after airway injec-
tion of normal saline (NS) or LPS. For the control
group, 120 μL NS was injected into the airway and
5.6 mL/kg NS was injected intraperitoneally 1 h before
and every 24 h after airway injection. For the model
group, 120 μL LPS, and 5.6 mL/kg NS were injected
intraperitoneally 1 h before and every 24 h after airway
injection. For the low dose intervention group, 120 μL
LPS was injected into the airway, and 2.8 mL/kg Tan-
reqing was injected intraperitoneally 1 h before and ev-
ery 24 h after airway injection. For the high dose Tan-
reqing intervention group, 120 μL LPS was injected in-
to the airway, and 5.6 mL/kg Tanreqing was injected
intraperitoneally 1 h before and every 24 h after airway
injection.
Collection of bronchial lung tissue
After anesthesia with intraperitoneal injection of 4%
pentobarbital sodium (40 mg/kg), rats were fixed on a
rat board and sacrificed by femoral artery bloodletting.
The right hilar was closed with RNAse-processed he-
mostatic forceps and the right lung taken. The upper
lobe of the right lung was kept in liquid nitrogen for
RNA extraction and the middle lobe fixed with 4%
paraformaldehyde buffer (pH 7.4) prior to paraffin em-
bedding.
Collection of BALF
After the right lung was taken, the neck skin was cut
and a small transverse incision on the lower trachea
was made. A blunt steel head with diameter of about
1 mm was inserted and fixed by operation thread, and
2 mL NS injected by a 5 mL-syringe. After reserving
for 2 min, it was slowly aspirated. BALF was collected
using a 10 mL-sterilized centrifugation tube, repeated
3 times in a total of 6 mL. A recovery rate >90% was
achieved. For each BALF specimen, 300 μL BALF was
added into a 1.5 mL-EP tube for cell count and classifi-
cation, and the remaining sample centrifuged at 4℃ ,
4000 rpm, for 5 min. The supernatant was poured into
EP tubes and kept at -80℃ for cytokine quantification.
Quantification of IL-1β, CINC-1, and TNF-α
IL-1β, CXCL-1/CINC-1, and TNF-α levels were
quantified by double antibody sandwich ELISA with a
detection wavelength of 450 nm and excitation wave-
length of 630 nm for IL-1β and 570 nm for CXCL-1/
CINC-1, and TNF-α.
Lung tissue HE staining
Lung sections (4 μm) were fixed by conventional paraf-
fin embedding. Slides treated with xylene and ethanol
gradient elution (xylene 2×10 min, followed by 2 min
each in anhydrous ethanol, then 95%, 85%, and 75%
ethanol, with a tap water flush 5 min). Slides were
then stained with Campeachy for 5 min, followed by a
tap-water flush, 1% hydrochloric acid alcohol separation
for 15 seconds, and a final water flushing for 5 min.
Slides were then stained with 1% eosin for 1 min, and
conventional dehydration, and mounting (2 min each
in 75%, 85%, 95% ethanol, then anhydrous ethanol,
followed by xylene for 2 min), and neutral gum mount-
ing.
Statistical methods
The data were analyzed by SPSS 17.0 software
(SPSS Inc., Chicago, IL, USA). Data were normally
distributed and expressed as mean±SD. P<0.05 was re-
garded as statistically significant. Tests of normality
and analysis of variance (ANOVA) was adopted, assum-
ing equal variance. If test results were statistically signif-
icant, the SNK method was adopted for future compar-
isons. Non-parameter tests were used for data assum-
ing equal variance. A Chi-square test was used for com-
parison of multi-rates.
RESULTS
Changes in total cell and neutrophil number in
BALF
In the blank control group, the total cell and neutro-
phil counts peaked at 24 h, declined gradually up to
48 h and stabilized at 96 h. Similarly, the high dose
Tanreqing intervention decreased BALF total cell and
neutrophil counts, with no significant difference be-
tween high and low dose Tanreqing intervention (Ta-
bles 1, 2). Total cell and neutrophil counts in BALF
at 24, 48, and 96 h were low with no significant
change.
IL-1 β and CINC-1 changes in BALF
IL-1β and CINC-1 levels in model animals peaked at
24 h, declined gradually up to 48 h and decreased
through 96 h, but still rose significantly higher than
control levels. Compared with the model group, IL-1β
and CINC-1 levels decreased in both the low and high
dose Tanreqing intervention group, with no significant
differences between the two groups (Tables 3, 4).
BALF IL-1β and CINC-1 levels at 24, 48, and 96 h in
the blank control group did not change significantly
and was maintained at a low level.
TNF-α level changes in BALF
TNF-α levels peaked at 24 h, declined through 48 h,
and reached the level of the blank control group by 96 h.
TNF-α levels in both the low dose and high dose Tanreq-
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ing intervention group decreased to control levels at 48
h, with no significant difference between the two
groups. TNF-α levels were similar among all groups at
96 h (Table 5). TNF-α levels were similar at 24, 48, 96
h and were maintained at a low level in the blank con-
trol group.
Pathological changes of lung tissue
We evaluated gross lung pathology. There was no obvi-
ous swelling and bleeding in the blank control group,
as the lung contained a pink luster. Model group lungs
at 24 and 48 h were dark red with marked hyperemia,
swelling, and many spotty and flaky hemorrhagic focus-
Group
Blank control
Model
Low dose Tanreqing intervention
High dose Tanreqing intervention
24 h
18±8
340±29a
259±25b
236±31b
48 h
16±6
293±49a
212±16b
183±27b
96 h
15±3
168±24ac
115±13b
96±8b
Table 1 Changes in total cell counts in BALF (×104/mL, xˉ ±s)
Notes: blank control: treated only with physiological saline; model group: treated with lipopolysaccharide and physiological saline; low
dose Tanreqing intervention: treated with lipopolysaccharide and a Tanreqing injection of 2.8 mL/kg; high dose Tanreqing intervention:
treated with lipopolysaccharide and a Tanreqing injection of 5.6 mL/kg. BALF: bronchoalveolar lavage fluid. Compared with the blank
control group, aP<0.05; compared with the model group, bP<0.05; compared with the same group at 48 h, cP<0.05.
Group
Blank control
Model
Low dose Tanreqing intervention
High dose Tanreqing intervention
24 h
1.48±0.78
286.48±30.99a
221.34±41.07b
199.91±26.64b
48 h
0.57±0.46
245.49±56.24a
171.03±14.34b
133.10±28.50b
96 h
0.37±0.25
92.87±11.03ac
43.32±13.38b
30.47±5.95b
Table 2 Changes in neutrophil count in BALF (×104/mL, xˉ ±s)
Notes: blank control: treated only with physiological saline; model group: treated with lipopolysaccharide and physiological saline; low
dose Tanreqing intervention: treated with lipopolysaccharide and a Tanreqing injection of 2.8 mL/kg; high dose Tanreqing intervention:
treated with lipopolysaccharide and a Tanreqing injection of 5.6 mL/kg. BALF: bronchoalveolar lavage fluid. Compared with the blank
control group, aP<0.05; compared with the model group, bP<0.05; compared with the same group at 48 h, cP<0.05.
Group
Blank control
Model
Low dose Tanreqing intervention
High dose Tanreqing intervention
24 h
69±20
617±76a
443±103b
408±88b
48 h
61±9
556±38a
237±21b
199±25b
96 h
59±7
223±78ac
121±13b
88±22b
Table 3 Changes of IL-1β in BALF (pg/mL, xˉ ±s)
Notes: blank control: treated only with physiological saline; model group: treated with lipopolysaccharide and physiological saline; low
dose Tanreqing intervention: treated with lipopolysaccharide and a Tanreqing injection of 2.8 mL/kg; high dose Tanreqing intervention:
treated with lipopolysaccharide and a Tanreqing injection of 5.6 mL/kg. IL-1β: interleukin-1β; BALF: bronchoalveolar lavage fluid. Com-
pared with the blank control group, aP<0.05; compared with the model group, bP<0.05; compared with the same group at 48 h, cP<0.05.
Group
Blank control
Model
Low dose Tanreqing intervention
High dose Tanreqing intervention
24 h
46±4
403±49a
340±34b
308±52b
48 h
44±9
348±44a
218±24b
176±25b
96 h
43±7
170±24ac
105±11b
81±14b
Table 4 Changes of CINC-1 levels in BALF (pg/mL, xˉ ±s)
Notes: blank control: treated only with physiological saline; model group: treated with lipopolysaccharide and physiological saline; low
dose Tanreqing intervention: treated with lipopolysaccharide and a Tanreqing injection of 2.8 mL/kg; high dose Tanreqing intervention:
treated with lipopolysaccharide and a Tanreqing injection of 5.6 mL/kg. CINC-1: cytokine-induced chemoattractant-1; BALF: bronchoal-
veolar lavage fluid. Compared with the blank control group, aP<0.05; compared with the model group, bP<0.05; compared with the same
group at 48 h, cP<0.05.
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es on the surface. At 96 h the pulmonary congestion
and swelling alleviated, and the hemorrhagic focus on
the lung surface decreased. Following intervention, the
pulmonary congestion, swelling, and degree of bleed-
ing in both the low and high dose Tanreqing groups
was alleviated to some extent compared with the model
group.
Pathological changes in the lung were visualized by hae-
matoxylin and eosin (HE) staining. The tracheal wall
integrity was maintained in the blank control group,
with no or little inflammatory cell infiltration. In the
model group, tracheal epithelial cells were partially
damaged and shed 24 h after LPS stimulation, lumen
secretions increased, and the airway lumen was sur-
rounded by a large number of inflammatory cells
around the blood vessels. Inflammatory cell infiltration
was reduced slightly by 48 h and further reduced by 96
h, although some still existed. At the same time points,
Tanreqing injection slightly mitigated inflammatory
cell infiltration, with more obvious effects seen follow-
ing the high dose Tanreqing injection (Figure 1).
DISCUSSION
The choice of experimental animals and evaluation
of airway inflammation
Some scholars have used LPS injection to establish an
airway inflammation model. The key element of build-
ing a successful airway inflammation model is the
choice of LPS sensitive animals, because different ex-
perimental animals have different sensitivity to LPS.
Sheep are sensitive to LPS, but their lungs are rich in
lymphatics, such that they are often used for lung lym-
phatic fistula experiments. The rabbit has intermediary
sensitivity to LPS, with a high mortality rate in models
that have been developed. Dogs are insensitive to LPS,
and mouse and rat have a certain resistance to LPS.
Therefore, to establish mouse or rat model, it is neces-
sary to determine an appropriate LPS dose to initiate
airway inflammation and not cause death.16-18
LPS activates an inflammatory reaction mainly
through two signaling pathways. Combinations of LPS
and LBP (lipopolysaccharide binding protein) are trans-
ferred to the medullar cell surface, which are glycosyl
anchored to CD14. The combination of
LPS-LBP-CD14 complex and TLR4 on the extracellu-
lar membrane (MD2 can enhance the effect) conducts
signals to intracellular TIR, which prompt protein
MyD88 to interact and promote activation of MyD88
death domain and IRAK-1. Activation of TRAF-6 af-
ter IRAK-1 auto-phosphorylation promotes interaction
of TRAF-6 and kinase TAK-1 (through protein TAB),
with the composite dimer enzyme composed of Uev1A
and Ubc13. Phosphorylation activates IKK, stimulat-
ing IκB (NF-B inhibiting protein) phosphorylation af-
ter NF-κB transfer to the nucleus, initiating transcrip-
tion of TNF-α, IL-1β, IL-8, and other inflammatory
proteins. In addition, the combination of MyD88 and
IRAK-1 activates the MAPKKK-MAPKK-MAPK cas-
cade reaction and selectively activates p38α, which
then moves into the nucleus and ultimately activates
AP1 and other transcription factors.19-21
In this study, we selected the rat as the experimental
model based on preliminary experiments as referenced
by Ou et al,13 who established an airway inflammation
model in rat with a one-time airway injection of E. coli
LPS. To ensure precise injection LPS, a 1 mL aseptic
die cavity insulin syringe was adopted and found that
120 μL LPS (240 μg LPS) induced shedding of rat air-
way epithelium and infiltration of inflammatory cells
around the trachea and blood vessels, indicating that
an airway inflammation model was established.
Choice of observation time points in the experiment
Yanagihara et al 22 adopted a one-time injection of Pseu-
domonas aeruginosa LPS into the airway of C57BL6
female mice to establish an inflammation model. They
found that airway inflammation peaked on the 2nd
day after LPS stimulation, declined slightly on the 4th
day, and decreased up to the 7th day. Our preliminary
experiments indicated that 24 h after LPS stimulation,
BALF inflammatory cell infiltration in lung were more
obvious than at 48 h. We selected 24, 48, and 96 h af-
ter LPS stimulation as observation points, to clearly de-
fine dynamic changes of LPS-induced airway inflam-
mation. If the observation time was too long, the ani-
mals would be susceptible to cross infection and affect
the experimental results, and mortality would increase.
Group
Blank control
Model
Low dose Tanreqing intervention
High dose Tanreqing intervention
24 h
32±6
135±13a
78±11b
64±7b
48 h
27±7
65±19a
30±7b
27±4b
96 h
27±4
29±5ac
28±5
28±4
Table 5 Changes of TNF-α in BALF (pg/mL, xˉ ±s)
Notes: blank control: treated only with physiological saline; model group: treated with lipopolysaccharide and physiological saline; low
dose Tanreqing intervention: treated with lipopolysaccharide and a Tanreqing injection of 2.8 mL/kg; high dose Tanreqing intervention:
treated with lipopolysaccharide and a Tanreqing injection of 5.6 mL/kg. TNF-α: tumor necrosis factor-α; BALF: bronchoalveolar lavage
fluid. Compared with the blank control group, aP<0.05; compared with the model group, bP<0.05; compared with the same group at 48 h,
cP<0.05.
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Selection of indices for monitoring degree of airway
inflammation
Increasing degrees of BALF total cell and neutrophil
counts can be used as indices for assessing the degree of
airway inflammation.23,24 To avoid the influence of red
blood cell count on total BALF cell counts, BALF pro-
cessing and cell classification was performed with eryth-
rocyte lysis buffer, which effectively removes red blood
cells without damaging karyocytes. IL-1β and TNF-α
are proinflammatory cytokines. Monocytes/macro-
phages, fibroblasts, T-lymphocytes, neutrophils, and
airway epithelial cells produce IL-1β. However, the
monocyte/macrophage lineage is the main source.
IL-1β is an endogenous pyrogen and promotes release
of neutrophils from bone marrow into the inflamma-
tion site, inducing a number of cells to produce IL-6,
IL-8, GM-CSF, TNF, and RANTES. These factors in-
duce expression of vascular endothelial cell adhesion
molecules, intercellular adhesion molecule-1, and vas-
cular cellular adhesive molecula-1, which correlates
with the number of neutrophils and eosinophils, adhe-
sion of vascular endothelial cells and respiratory epithe-
lium cells, IL-1β concentration, and sputum macro-
phage cell count.25 TNF-α is produced by macro-
phages, T-lymphocytes, mast cells and epithelial cells,
with macrophages being the main source. It is also an
endogenous pyrogen and promotes neutrophil degranu-
lation, and activates NF-kB and p38 MAPK, initiating
transcription of inflammatory genes and stimulating
airway epithelial cells and neutrophils to produce IL-8,
GM-CSF, and RANTES.26,27 IL-8 is a CXC chemotac-
tic factor with strong chemotaxis activation of neutro-
phils and T lymphocytes. BALF IL-8 concentration is
correlated with airway neutrophil count, respiratory
tract bacteria load, and myeloperoxidase levels, and
serves as an index for assessing airway inflammation.28,29
CINC-1 belongs to the IL-8 chemokine family and
tends to mediate neutrophil inflammation in inflamma-
tory diseases.30-32 In COPD patients IL-1β, TNF-α,
IL-8, and IL-6 sputum levels increase at the stationary
phase and during the acute deteriorative phase.33,34 In-
flammatory cells and inflammatory factors play an im-
portant role in a variety of biological effects induced by
LPS. Therefore, in this experiment, we selected cell to-
Figure 1 Pathological changes of lung visualized by HE staining (×400)
A: blank control group at 24 h; B: model group at 24 h; C: low dose Tanreqing intervention group at 24 h; D: high dose Tanreqing
intervention group at 24 h; E: blank control group at 48 h; F: model group at 48 h; G: low dose Tanreqing intervention group
at 48 h; H: high dose Tanreqing intervention group at 48 h; I: blank control group at 96 h; J: model group at 96 h; K: low dose Tan-
reqing intervention group at 96 h; L: high dose Tanreqing intervention group at 96 h. Blank control: treated only with physiologi-
cal saline; model group: treated with lipopolysaccharide and physiological saline; low dose Tanreqing intervention: treated with li-
popolysaccharide and a Tanreqing injection of 2.8 mL/kg; high dose Tanreqing intervention: treated with lipopolysaccharide and
a Tanreqing injection of 5.6 mL/kg. HE: haematoxylin and eosin.
LI J K
A B C D
E F G H
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tal count, neutrophil count, BALF levels of IL-1β,
TNF-α, and CINC-1, and pathological changes in the
lung as indices for assessing the degree of inflammation.
Dynamic changes of rat airway inflammation
caused by LPS
In the model group, the above indexes peaked at 24 h
after LPS injection and began to decline at 48 h before
stabilizing at 96 h. TNF-α levels were reduced to the
level of the blank group. Lung tissue pathology of
H&E staining did not reveal significant changes.
BALF IL-1β, CINC-1, TNF-α levels, and total cell
and neutrophil counts did not change significantly in
the blank control group after airway NS injection.
Arsalane et al 35 reported that BALF total cell and neu-
trophil counts peaked at 6 h after injection of 200 μL
E. Coli LPS (100 μg LPS) in the male SD rat, began
to decline 24 h, decreased further at 48 h, and reached
baseline at 72 h. Ulich et al 36 observed that 2 h after in-
jection of S. typhi LPS (100 μg) into Lewis rat, BALF
neutrophil number began to rise, peaked at 6-24 h,
and decreased to near baseline at 48-72 h. Liaudet
found that airway inflammation peaked 24 h after LPS
injection, and resolved at about 3 days.37 These results
are consistent with characteristics associated with acute
airway inflammation. Peak inflammation occurred at
different time points due to differences in concentra-
tion, dose, LPS administration method, experimental
animal, and observation time points.
Intervention and dose-effect relationship of
Tanreqing injection
We found that after Tanreqing injection intervention,
total cell and neutrophil counts, BALF IL-1β,
CINC-1, and TNF-α levels, and pathological changes
were reduced to a similar extent as compared with the
model group. In contrast, the high dose Tanreqing in-
tervention group exhibited more obvious changes. Tan-
reqing injection anti-inflammatory effects exhibit a
dose-response relationship, but the difference between
the two groups was not statistically significant.
Li et al 38 found that Tanreqing injection reduces in-
flammatory cell counts and BALF TNF-α levels, effec-
tively inhibiting the ALI-induced decreases and oxygen
partial pressure. This alleviated pulmonary interstitial
edema and inflammatory cell infiltration, but did not
display a dose-response relationship. Interestingly, Pan
et al 39 found Tanreqing injection could suppress an in-
flammatory reaction and endotoxemia state, reducing
blood TNF-α and IL-1β levels, but did not show a
dose-response relationship. These results suggest that
Tanreqing injection has a certain anti-inflammatory ef-
fect on endotoxin related diseases, which is consistent
with our results.
A dose-response relationship is influenced by individu-
al differences, route of administration, and drug dosage
form, among other factors. Chinese drugs have differ-
ent dose-effect relationships from Western drugs, with
influencing factors more complicated than for Western
Medicine. Because of complex compositions and mech-
anism of action of Chinese drugs, individual animal
differences, and limited sample size, a dose-effect rela-
tionship is not easily determined. This study found
that high dose had a stronger anti-inflammatory effect
than low dose Tanreqing injection, although the differ-
ences were not statistically significant. This suggests
that low and high dose Tanreqing injections have simi-
lar anti-inflammatory effects, or that a statistical differ-
ence was not observed owing to the small sample size.
REFERENCES
1 Tetley TD. Inflammatory cells and chronic obstructive
pulmonary disease. Curr Drug Targets Inflamm Allergy
2005; 4(6): 607-618.
2 Chung KF. Inflammatory mediators in chronic obstruc-
tive pulmonary disease. Curr Drug Targets Inflamm Aller-
gy 2005; 4(6): 619-625.
3 Barnes PJ. Mediators of chronic obstructive pulmonary
disease. Pharmacol Rev 2004; 56(4): 515-548.
4 Di Stefano A, Capelli A, Lusuardi M, et al. Severity of air-
flow limitation is associated with severity of airway inflam-
mation in smokers. Am J Respir Crit Care Med 1998; 158
(4): 1277-1285.
5 Barnes PJ. New concepts in chronic obstructive pulmo-
nary disease. Annu Rev Med 2003; 54(2): 113-129.
6 O'Donnell R, Breen D, Wilson S, et al. Inflammatory
cells in the airways in COPD. Thorax 2006; 61(5):
448-454.
7 Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and
management of stable chronic obstructive pulmonary dis-
ease: a clinical practice guideline update from the Ameri-
can College of Physicians, American College of Chest Phy-
sicians, American Thoracic Society, and European Respira-
tory Society. ANN INTERN MED 2011; 155(3):
179-191.
8 Gan WQ, Man SF, Sin DD. Effects of inhaled corticoste-
roids on sputum cell counts in stable chronic obstructive
pulmonary disease: a systematic review and a meta-analy-
sis. BMC Pulm Med 2005; 5(3): 1-14.
9 Yue YY, Li YC. Experimental study on protective effects of
Salvia on airway in the chronic obstructive pulmonary dis-
ease rat model. Lin Chuang He Li Yong Yao 2011; 4(8C):
15-17.
10 Li XC, Yin Y. Effects of modified Yuebijiabanxia decoc-
tion on serum IL-8 and TNF-α in COPD model rats. Wu
Jing Yi Xue Yuan Xue Bao 2011; 20(6): 472-474.
11 Lee H, Lee D, Kim Y, et al. Lipopolysaccharide-induced
lung inflammation is inhibited by Lonicera japonica. Mol
Cell Toxicol 2011; 7(1): 87-93.
12 Liu YB, Shen WG, Liu LL. Effects of Runfei Oral Liquid
on expressions of TNF-α, ICAM-1 protein and IL-8 in
bronchus of the rat with chronic bronchial inflammation.
Zhong Guo Lao Nian Yi Xue Za Zhi 2007; 27(1): 8-11.
13 Ou XM, Feng YL, Wen FQ, et al. Macrolides attenuate
mucus hypersecretion in rat airway through inactivation of
NF-kappaB. Respirology 2008; 13(1): 63-72.
511
JTCM |www. journaltcm. com
Dong SJ et al. / Experimental Study
August 15, 2013 |Volume 33 | Issue 4 |
14 Deng XL, Zhong XG, Zhang XJ, et al. Protective effect of
Tanreqing injection on immunological liver injury. Zhong
Guo Zhong Yao Za Zhi 2011; 36(5): 636-638.
15 Shi XY. Medical laboratory animal sciences. Xian: Shanxi
Science and Technology Press, 1989: 422.
16 Redl H, Bahrami S, Schlag G, et al. Clinical detection of
LPS and animal models of endotoxemia. Immunobiology
1993; 187(3-5): 330-345.
17 Matute-Bello G, Frevert CW, Martin TR. Animal models
of acute lung injury. Am J Physiol Lung Cell Mol Physiol
2008; 295(3): L379-L399.
18 Luo XH, Wan DJ, Niu XT, et al. The protective effect of
ulinastatin on multiple organ dysfunction syndromes of
sheep. Zhong Guo Lao Nian Duo Qi Guan Ji Bing Za
Zhi 2011; 10(5): 431-434.
19 Bishop RE. Fundamentals of endotoxin structure and
function. Contrib Microbiol 2005; 12(1): 1-27.
20 Wang XJ, Quinn PJ. Endotoxins: structure, function and
recognition. Springer-Verlag: Springer Science Business
Media, 2010: 153-170.
21 Zhang H, Li L, Mao EQ. P38 and sepsis. Sheng Ming Ke
Xue 2007; 19(4): 417-422.
22 Yanagihara K, Seki M, Cheng PW. Lipopolysaccharide in-
duces mucus cell metaplasia in mouse lung. Am J Respir
Crit Cell Mol Biol 2001; 24(1): 66-73.
23 Gorska K, Krenke R, Domagala-Kulawik J, et al. Compar-
ison of cellular and biochemical markers of airway inflam-
mation in patients with mild-to-moderate asthma and
chronic obstructive pulmonary disease: an induced spu-
tum and bronchoalveolar lavage fluid study. J Physiol Phar-
macol 2008; 59(Suppl 6): 271-283.
24 Shimura S. Bronchoalveolar lavage in diagnosis of chronic
obstructive pulmonary disease. Nihon Rinsho 1999; 57
(9): 2005-2011.
25 Sapey E, Ahmad A, Bayley D, et al. Imbalances between
interleukin-1 and tumor necrosis factor agonists and antag-
onists in stable COPD. J Clin Immunol 2009; 29(4):
508-516.
26 Chung KF. Cytokines in chronic obstructive pulmonary
disease. Eur Respir J 2001; 34(Suppl): 50s-59s.
27 Chung KF. Inflammatory mediators in chronic obstruc-
tive pulmonary disease. Curr Drug Targets Inflamm Aller-
gy 2005; 4(6): 619-625.
28 Di Stefano A, Capelli A, Donner CF. Role of interleu-
kin-8 in the pathogenesis and treatment of COPD. Chest
2004; 126(3): 676-678.
29 Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway in-
flammation in COPD assessed by sputum levels of inter-
leukin-8. Chest 1997; 112(2): 505-510.
30 Watanabe K, Suematsu M, Iida M, et al. Effect of rat
CINC/gro, a member of the interleukin-8 family, on leu-
kocytes in microcirculation of the rat mesentery. Exp Mol
Pathol 1992; 56(1): 60-69.
31 Watanabe K, Koizumi F, Kurashige Y, et al. Rat CINC, a
member of the interleukin-8 family, is a neutrophil-specif-
ic chemoattractant in vivo. Exp Mol Pathol 1991; 55(1):
30-37.
32 Iida M, Watanabe K, Tsurufuji M, et al. Level of neutro-
phil chemotactic factor CINC/gro, a member of the inter-
leukin-8 family, associated with lipopolysaccharide-in-
duced inflammation in rats. Infect Immun 1992 Apr; 60
(4): 1268-1272.
33 Keatings VM, Collins PD, Scott DM, et al. Differences
in interleukin-8 and tumor necrosis factor-α in induced
sputum from patients with chronic obstructive pulmonary
disease or asthma. Am J Respir Crit Care Med 1996; 153
(2): 530-534.
34 Tsoumakidou M, Tzanakis N, Siafakas NM. Induced spu-
tum in the investigation of airway inflammation of
COPD. Respir Med 2003; 97(8): 863-871.
35 Arsalane K, Broeckaert F, Knoops B, et al. Clara cell spe-
cific protein (CC16) expression after acute lung inflamma-
tion induced by intratracheal lipopolysaccharide adminis-
tration. Am J Respir Crit Care Med 2000; 161(5):
1624-1630.
36 Ulich TR, Waston LR, Yin SM, et al. The intratracheal ad-
ministration of endotoxin and cytokines. I. Characteriza-
tion of LPS-induced IL-1 and TNF mRNA expression
and the LPS-, IL-1, and TNF-induced inflammatory infil-
trate. Am J Pathol 1991; 138(6): 1485-1496.
37 Liaudet L, Pacher P, Mabley JG, et al. Activation of poly
(ADP-Ribose) polymerase-1 is a central mechanism of li-
popolysaccharide-induced acute lung inflammation. Am J
Respir Crit Care Med 2002; 165(3): 372-377.
38 Li PT, Zhang N, Zhu XL, et al. Experimental study on ef-
fect of Tanreqing Injection on acute lung injury induced
by endotoxin injection. Zhong Guo Yao Xue Za Zhi
2005; 40(7): 518-521.
39 Pan YS, Zhang N, Zhu XL, et al. Correlative research on
Tanreqing Injection intervening the pathological process
of endotoxemia. Zhong Guo Zhong Yi Ji Chu Za Zhi
2005; 11(7): 508-510.
512
